NEW TAIPEI CITY , Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for ...
PARAMUS, N.J. , Jan. 22, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed ...
Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial ...
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January , 2024 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug ...
Treatment with IPL344 was well tolerated Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression (p=0.028); and 64% slower progression when adjusted for disease stage and rate (p=0.034) Study suggests benefits ...
GUANGZHOU, China , Jan. 10, 2024 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain, has announced today ...
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. ...
SHENZHEN, China , Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection , securing exclusive commercialization licensing ...
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this ...
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ...
Dapagliflozin, a medication prescribed for managing Type 2 diabetes , has demonstrated additional benefits in heart failure conditions. This drug lowers the likelihood of hospitalization due to heart failure and mortality in ...
The efficacy of mRNA vaccine technology demonstrated during the COVID-19 pandemic provides optimism for its utilization in mitigating preventable illnesses across various disease domains ( ). ...
An intradermal monkeypox (Mpox) vaccination regimen with reduced dosage proved safe and elicited an antibody response comparable to the standard regimen at six weeks (two weeks post-second dose). ...
The World Health Organization (WHO) granted prequalification to a novel oral cholera vaccine on April 12. The Euvichol-S oral vaccine, which is inactivated, demonstrates comparable effectiveness to the current vaccines, ...
Alectinib, a molecule developed by Genentech, Inc has been granted approval by the Food and Drug Administration on April 18, 2024, for the adjuvant treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers